Patent ID: 6699846
Filing Date: 2004-03-02
Classification: A61K,A61P,C07H

Abstract:
A method for treating diseases or conditions ameliorated by nitric oxide production in a subject comprising contacting said subject with an effective amount of a compound of the formula: and pharmaceutically acceptable salts thereof, whereinX is a member selected from the group consisting of â€”Oâ€” and â€”NHâ€”; R1 and R2 are each members independently selected from the group consisting of (C2-C24)acyl; R3 is a member selected from the group consisting of â€”H and â€”PO3R11R12, wherein R11 and R12 are each members independently selected from the group consisting of â€”H and (C1-C4)alkyl; R4 is a member selected from the group consisting of â€”H, â€”CH3 and â€”PO3R13R14, wherein R13 and R14 are each members independently selected from the group consisting of â€”H and (C1-C4)alkyl; and Y is a radical selected from the group consisting of and wherein the subscripts n, m, p and q are each independently an integer of from 0 to 6; R5 is (C2-C24)acyl; R6 and R7 are members independently selected from the group consisting of H and CH3; R8 and R9 are members independently selected from the group consisting of H, OH, (C1-C4)alkoxy, â€”PO3H2, â€”OPO3H2, â€”SO3H, â€”OSO3H, â€”NR15R16, â€”SR15, â€”CN, â€”NO2, â€”CHO, â€”CO2R15, and â€”CONR15R16, wherein R15 and R16 are each members independently selected from the group consisting of H and (C1-C4)alkyl; R10 is a member selected from the group consisting of H, CH3, â€”PO3H2, &ohgr;-phosphonooxy(C2-C24)alkyl, and &ohgr;-carboxy(C1-C24)alkyl; and Z is â€”Oâ€” or â€”Sâ€”; with the proviso that when R3 is â€”PO3R11R12, R4 is other than â€”PO3R13R14, and further proviso that when R3 is â€”PO3H2, R4 is H, R10 is H, R1 is n-tetradecanoyl, R2 is n-octadecanoyl and R5 is n-hexadecanoyl, then X is other than â€”Oâ€”, providing that the compound is other than monophosphoryl lipid A or 3-deacylated monophosphoryl lipid A.